*By Conor White*
The positive [news](https://cheddar.com/videos/tesla-stock-surges-after-q2-earnings-report) in Tesla's second quarter earnings report outweighed the negatives for most investors, sending shares up more than 12 percent to their highest level in a month.
The electric carmaker announced that Model 3 production is up, but it posted losses of more than $700 million.
Some analysts have fundamental doubts about Tesla's future.
"It's a story stock," said Mark Spiegel, managing member at Stanphyl Capital. "What you have here are: bulls who couldn't care less about balance sheets or profit and loss statements; and you've got bears, or as I would call them, realists, who care a lot about that kind of stuff."
Spiegel counts himself in the latter group. He said in an interview Thursday on Cheddar that Tesla didn't do nearly enough to assuage fears about its future ー and that doesn't even account for all the other car companies eager for a bigger slice of the electric vehicle industry.
"There's a massive amount of competition coming for this company," Speigel said. "Between the Jaguar that's out now and the Audi, Mercedes, and Porsche coming out next year, it's going to destroy Model S and X sales, and that's where \[Tesla's\] margin isーwhatever margin they have."
And even though [outspoken](https://cheddar.com/videos/will-elon-musk-behave-on-this-weeks-earnings-call) CEO Elon Musk behaved on this conference call, there's no telling what he will do next.
After reaching its production goal of 5,000 Model 3 cars per week, Tesla reports it now wants to churn out 10,000 per week, "as fast as we can."
Spiegel dismissed those numbers ー and Tesla more generally.
"They're a perennial over-promiser and under-deliverer," he said.
"The reason they keep putting out these aggressive numbers is it supports the stock, which is an absurd valuation. If Tesla were a normal car company losing this much money, the stock would be in the low single digits."
For more on this story, [click here](https://cheddar.com/videos/tesla-announces-biggest-loss-ever-but-shares-rally).
Catching you up on what you need to know on April 18, 2022, with Russian missile attacks on the Ukrainian city of Lviv killing seven, mass shootings in South Carolina and Pittsburgh, Lucky Charms cereal under official investigation by the FDA, and more.
Lisa Whalen, Automotive and Mobility Analyst at Morning Consult, joined Cheddar News' Closing Bell to break down the famed auto show's emphasis on electric vehicles this year, reflecting a shift toward electrification in the automotive industry.
Peggy Whitson, Director of Human Space Flight, Axiom Space, joins Cheddar Innovates to discuss Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space.
On this episode of Cheddar Innovates, Peggy Whitson, Director of Human Space Flight, Axiom Space, breaks down Axiom's involvement in the first fully-private mission to the ISS, and her experience spending 665 days in space; William Li and Danielle Chang, co-founders of The Hao Life, discuss how they're shaking up the $71 billion supplement industry by putting a modern spin on traditional natural Chinese remedies; Cheddar gets a look at Curiosity Stream's 'Sagrada Familia: Gaudi's Challenge.'
On this episode of Cheddar Innovates: President of The Pillow Bar breaks down how everyone can benefit from a pillow customized to their unique way of sleeping; CEO of H2Pro explains how to bring environmentally friendly hydrogen to scale; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
On this episode of Cheddar Innovates: Gardenuity CEO breaks down how gardening can improve your wellbeing; Augmedix CEO discusses how this technology is helping doctors fight burnout; Cheddar gets a look at Curiosity Stream's 'Suppressed Science.'
On this episode of Cheddar Innovates: Atom Limbs CEO breaks down how the Atom Touch prosthetic is different from other prosthetics on the market; CEO & Chief Scientific Officer of MyMD explains how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases; A look at Curiosity Stream's 'The Future of Warfare.'
